chloroquine and derivatives - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.09 [0.99, 1.21]< 10%25 studies (25/-)4.6 %highlow lowcrucial-
deaths (time to event analysis only) 1.10 [0.99, 1.23]< 10%2 studies (2/-)3.9 %some concernnot evaluable moderatecrucial-
clinical deterioration 1.00 [0.46, 2.17]< 141%3 studies (3/-)50.5 %highnot evaluable lowimportant-
clinical improvement 1.21 [0.88, 1.67]> 137%4 studies (4/-)87.6 %highnot evaluable lowimportant-
clinical improvement (14-day) 1.17 [0.62, 2.23]> 120%2 studies (2/-)68.6 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.01 [0.59, 1.74]> 10%1 study (1/-)51.7 %highnot evaluable lowimportant-
death or ventilation 1.14 [1.03, 1.25]< 10%3 studies (3/-)0.5 %some concernnot evaluable moderateimportant-
hospitalization 0.79 [0.42, 1.48]< 10%2 studies (2/-)77.0 %some concernnot evaluable moderateimportant-
PCR-negative conversion 0.88 [0.63, 1.22]> 10%3 studies (3/-)22.1 %highnot evaluable lowimportant-
PCR-negative conversion (14-day) 0.91 [0.56, 1.48]> 10%2 studies (2/-)35.7 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 1.05 [0.53, 2.09]> 10%1 study (1/-)55.2 %NAnot evaluable important-
PCR-negative conversion (time to event analysis only) 0.85 [0.58, 1.23]> 10%1 study (1/-)19.3 %highnot evaluable lowimportant-
radiologic improvement (7-day) 3.43 [1.10, 10.70]> 10%1 study (1/-)98.3 %highnot evaluable lowimportant-
ICU admission 0.83 [0.35, 1.95]< 10%1 study (1/-)66.8 %some concernnot evaluable moderatenon important-

safety endpoints 00

cardiac arrest 1.92 [0.35, 10.49]< 10%1 study (1/-)22.7 %some concernnot evaluable moderateimportant-
adverse events 2.40 [1.12, 5.13]< 189%10 studies (10/-)1.2 %highlow lownon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.